Tue, Mar 3, 2015, 8:29 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

InterMune, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • wall_st_knight_mare wall_st_knight_mare Aug 20, 2012 7:12 PM Flag

    Can Someone Tell Me about this company

    WIDER LOSS

    InterMune loss from continuing operations widened to $50.9 million, or 78 cents per share, in the second quarter from $41.3 million, or 70 cents per share, a year earlier.

    Including the one-time payment from the sale of Actimmune, the company posted a net profit of $490,000, or 1 cent per share.

    Esbriet, which was rejected by the U.S. Food and Drug Administration in May 2010, is currently being studied in a late-stage trial.

    InterMune expects to complete enrollment by the year end. William Blair analyst Xu expects data from the trial by 2014.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
ITMN
73.890.00(0.00%)Sep 26 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.